You are here


Abilify (aripiprazole) is an atypical antipsychotic manufactured by Otsuka Pharmaceutical Co., Ltd marketed jointly with Bristol-Myers Squibb Canada. It was approved by FDA in November 2002 for the treatment of Schizophrenia. In 2007, FDA approved Aripiprazole for treatment of Unipolar depression as an adjunct with an antidepressant medication. The drug works by either increasing or decreasing dopamine or serotonin levels in the brain when there is an imbalance.

A large number of patients treated with Abilify were reported to develop habit of compulsive gambling and got racked up with large amounts of debts. Other pathological behaviors like excessive eating, excessive shopping and Hypersexuality is also noted who started using or increased dosage of Abilify.

Young patients with depression and elderly patients with dementia consuming Abilify are found to be at a high risk of suicidal thoughts or actions. It also increases risk of developing diabetes.

Serious Alleged Injuries:

  • Pathological Gambling
  • Binge Eating
  • Hypersexuality
  • Dementia Suicide Risk

FDA Warnings and Litigations

On 5 May, 2016 FDA issued warning that compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of the antipsychotic drug aripiprazole (Abilify, Abilify Maintena, Aristada, and generics). These uncontrollable urges were reported to have stopped when the medicine was discontinued or the dose was reduced.

A request for Black Box label warning is made by researchers about gambling addiction, hyper-sexuality, compulsive shopping and other impulsive disorders.

In the U.S. District Court for the Northern District of Florida, all the federal Abilify lawsuits are centralized into Multi-District Litigation (MDL No. 2734).

Evidence to be looked for in potential cases

  • Usage of Abilify in Pharmacy Records
  • Duration of Abilify usage
  • Indications for usage of Abilify in Medical Records
  • Complications and their Treatment after Abilify Intake

Medical Record Review and claim validation of Abilify case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.

or Contact Us for a Free Consultation!
Please fill out the details below, or e-mail us at Contact us for more info
Fields marked with '*' are mandatory.
Contact Number with Country code
Any additional information you would like to provide.
This selection is for testing whether you are a human visitor and to prevent automated spam submissions.
All fields are mandatory.